Skip to main content
. 2016 Oct 19;7(51):84872–84882. doi: 10.18632/oncotarget.12744

Table 5. Effects of five SNPs on breast cancer risk as stratified by expression of ER, PR, and HER-2.

Genotype Co ER (-) ER (+) PR (-) PR (+) HER-2 (-) HER-2 (+)
Ca OR(95% CI)* P value Ca OR(95% CI)* P value Ca OR(95% CI)* P value Ca OR(95% CI)* P value Ca OR(95% CI)* P value Ca OR(95% CI)* P value
XPA rs1800975
GG 93 51 Reference 64 Reference 61 Reference 54 Reference 27 Reference 88 Reference
GA 231 86 0.67(0.44,1.03) 0.067 149 0.93(0.64,1.36) 0.718 109 0.72(0.49,1.08) 0.113 126 0.93(0.62,1.39) 0.720 46 0.69(0.41,1.18) 0.177 189 0.86(0.60,1.22) 0.399
AA 106 35 0.60(0.36,1.01) 0.055 65 0.89(0.57,1.39) 0.602 42 0.61(0.37,0.99) 0.044 58 0.94(0.59,1.49) 0.786 24 0.78(0.42,1.45) 0.432 76 0.76(0.50,1.15) 0.196
GA/AA 337 121 0.65(0.44,0.98) 0.038 214 0.92(0.64,1.33) 0.670 151 0.69(0.47,1.00) 0.053 184 0.94(0.64,1.38) 0.747 70 0.73(0.44,1.20) 0.212 265 0.83(0.60,1.16) 0.284
ERCC1 rs11615
CC 261 98 Reference 132 Reference 119 Reference 111 Reference 47 Reference 183 Reference
TC 151 70 1.23(0.85,1.78) 0.276 125 1.63(1.18,2.24) 0.003 82 1.16(0.82,1.64) 0.414 113 1.78(1.28,2.48) 0.001 48 1.73(1.10,2.72) 0.018 147 1.38(1.03,1.87) 0.034
TT 18 4 0.58(0.19,1.76) 0.333 21 2.28(1.17,4.44) 0.015 11 1.34(0.61,2.94) 0.463 14 1.81(0.87,3.77) 0.114 2 0.66(0.15,2.95) 0.585 23 1.80(0.94,3.44) 0.075
TC/TT 169 74 1.16(0.81,1.66) 0.432 146 1.68(1.24,2.29) 0.001 93 1.17(0.84,1.64) 0.352 127 1.76(1.28,2.43) 0.001 50 1.61(1.03,2.51) 0.037 170 1.41(1.06,1.88) 0.018
XPC rs2228000
CC 228 84 Reference 117 Reference 96 Reference 105 Reference 41 Reference 160 Reference
CT 174 67 1.06(0.72,1.54) 0.773 131 1.48(1.08,2.04) 0.016 88 1.23(0.86,1.75) 0.257 110 1.38(0.99,1.92) 0.059 41 1.32(0.82,2.12) 0.257 157 1.30(0.97,1.75) 0.082
TT 28 21 2.27(1.20,4.26) 0.011 30 2.15(1.22,3.78) 0.008 28 2.62(1.45,4.73) 0.001 23 1.83(1.00,3.34) 0.049 15 3.09(1.50,6.36) 0.002 36 1.93(1.12,3.31) 0.017
CT/TT 202 88 1.21(0.85,1.72) 0.299 161 1.58(1.16,2.14) 0.004 116 1.41(1.01,1.96) 0.045 133 1.44(1.05,1.98) 0.026 56 1.55(0.99,2.42) 0.055 193 1.39(1.04,1.84) 0.025
XPC rs2228001
AA 161 72 Reference 121 Reference 94 Reference 99 Reference 43 Reference 150 Reference
AC 213 79 0.81(0.55,1.19) 0.277 116 0.72(0.52,1.00) 0.051 90 0.71(0.49,1.01) 0.055 105 0.80(0.57,1.13) 0.202 42 0.74(0.46,1.20) 0.220 153 0.76(0.56,1.04) 0.085
CC 56 21 0.80(0.45,1.42) 0.444 41 0.97(0.60,1.55) 0.894 28 0.81(0.48,1.37) 0.436 34 0.99(0.60,1.62) 0.958 12 0.77(0.38,1.58) 0.482 50 0.94(0.60,1.47) 0.790
AC/CC 269 100 0.81(0.56,1.16) 0.251 157 0.77(0.57,1.05) 0.098 118 0.73(0.52,1.02) 0.066 139 0.84(0.61,1.16) 0.284 54 0.75(0.48,1.18) 0.213 203 0.80(0.60,1.07) 0.133
ERCC2/XPD rs50872
CC 290 89 Reference 180 Reference 113 Reference 156 Reference 58 Reference 211 Reference
CT 126 73 1.86(1.28,2.71) 0.001 87 1.10(0.79,1.53) 0.588 85 1.71(1.20,2.43) 0.003 75 1.09(0.77,1.55) 0.621 36 1.43(0.89,2.28) 0.136 124 1.33(0.98,1.81) 0.069
TT 14 10 2.44(1.04,5.73) 0.040 11 1.27(0.56,2.86) 0.565 14 2.61(1.20,5.68) 0.016 7 0.93(0.37,2.36) 0.882 3 1.08(0.30,3.90) 0.905 18 1.80(0.88,3.72) 0.110
CT/TT 140 83 1.92(1.34,2.76) 0.000 98 1.11(0.81,1.53) 0.518 99 1.80(1.28,2.52) 0.001 82 1.08(0.77,1.51) 0.658 39 1.39(0.88,2.19) 0.157 142 1.38(1.03,1.85) 0.033
*

Adjusted by age and menopausal status; Ca, case; Co, control.